Novo Nordisk said Thursday that it was cutting the supply of some doses of its popular obesity drug in the U.S. as it struggles to keep up with surging demand.
© 2010-2022 Billy Tang
Supported By Growth SpeedUp Company
© 2010-2022 Billy Tang
Supported By Growth SpeedUp Company
Subscribe now to keep reading and get access to the full archive.